Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Lung Cancer

Free Subscription Articles published in J Cancer Res Clin Oncol Retrieve available abstracts of 89 articles: HTML format Text format

Single Articles

June 2019
1. PARK CK, Kim JE, Kim MS, Kho BG, et al
   Feasibility of liquid biopsy using plasma and platelets for detection of anaplastic lymphoma kinase rearrangements in non-small cell lung cancer.
   J Cancer Res Clin Oncol. 2019 Jun 1. pii: 10.1007/s00432-019-02944.
   PubMed     Text format     Abstract available
   
   
   
2. KOH YW, Han JH, Haam S, Jung J, et al
   ALDH1 expression correlates with an epithelial-like phenotype and favorable prognosis in lung adenocarcinoma: a study based on immunohistochemistry and mRNA expression data.
   J Cancer Res Clin Oncol. 2019;145:1427-1436.
   PubMed     Text format     Abstract available
   
   
   
3. SCHULER M, Tan EH, O'Byrne K, Zhang L, et al
   First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
   J Cancer Res Clin Oncol. 2019;145:1569-1579.
   PubMed     Text format     Abstract available
   
   
   May 2019
4. PARK JH, Kwon BS, Park SJ, Ji W, et al
   Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer.
   J Cancer Res Clin Oncol. 2019 May 29. pii: 10.1007/s00432-019-02941.
   PubMed     Text format     Abstract available
   
   
   
5. CHO JH, Jung HA, Lee SH, Ahn JS, et al
   Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma.
   J Cancer Res Clin Oncol. 2019;145:1341-1349.
   PubMed     Text format     Abstract available
   
   
   April 2019
6. ZHU J, Liu W, Chen C, Zhang H, et al
   TPP1 OB-fold domain protein suppresses cell proliferation and induces cell apoptosis by inhibiting telomerase recruitment to telomeres in human lung cancer cells.
   J Cancer Res Clin Oncol. 2019 Apr 23. pii: 10.1007/s00432-019-02921.
   PubMed     Text format     Abstract available
   
   
   
7. CHENG X, Yin H, Fu J, Chen C, et al
   Aggregate analysis based on TCGA: TTN missense mutation correlates with favorable prognosis in lung squamous cell carcinoma.
   J Cancer Res Clin Oncol. 2019;145:1027-1035.
   PubMed     Text format     Abstract available
   
   
   
8. MELLING N, Bachmann K, Hofmann B, El Gammal AT, et al
   Prevalence and clinical significance of RBM3 immunostaining in non-small cell lung cancers.
   J Cancer Res Clin Oncol. 2019;145:873-879.
   PubMed     Text format     Abstract available
   
   
   
9. WANG L, Liu J, Liu J, Chen X, et al
   GLRX inhibition enhances the effects of geftinib in EGFR-TKI-resistant NSCLC cells through FoxM1 signaling pathway.
   J Cancer Res Clin Oncol. 2019;145:861-872.
   PubMed     Text format     Abstract available
   
   
   March 2019
10. HAWKINS PG, Sun Y, Dess RT, Jackson WC, et al
    Circulating microRNAs as biomarkers of radiation-induced cardiac toxicity in non-small-cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Mar 28. pii: 10.1007/s00432-019-02903.
    PubMed     Text format     Abstract available
    
    
    
11. AHN BC, Pyo KH, Xin CF, Jung D, et al
    Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice.
    J Cancer Res Clin Oncol. 2019 Mar 25. pii: 10.1007/s00432-019-02899.
    PubMed     Text format     Abstract available
    
    
    
12. CHANG H, Lee SJ, Lim J, Lee JS, et al
    Prognostic significance of metabolic parameters measured by (18)F-FDG PET/CT in limited-stage small-cell lung carcinoma.
    J Cancer Res Clin Oncol. 2019 Mar 21. pii: 10.1007/s00432-019-02848.
    PubMed     Text format     Abstract available
    
    
    
13. FANG L, Wang L, Wang Y, Wu Y, et al
    Predictors and survival impact of station 4L metastasis in left non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2019 Mar 16. pii: 10.1007/s00432-019-02880.
    PubMed     Text format     Abstract available
    
    
    
14. CAMPLING BG, Ye Z, Lai Y, Li L, et al
    Disparity in age at lung cancer diagnosis between current and former smokers.
    J Cancer Res Clin Oncol. 2019 Mar 4. pii: 10.1007/s00432-019-02875.
    PubMed     Text format     Abstract available
    
    
    
15. ZHANG Y, Ma Y, Li Y, Shen X, et al
    Comparative analysis of co-occurring mutations of specific tumor suppressor genes in lung adenocarcinoma between Asian and Caucasian populations.
    J Cancer Res Clin Oncol. 2019;145:747-757.
    PubMed     Text format     Abstract available
    
    
    
16. SONG Q, Shang J, Zhang C, Zhang L, et al
    Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients.
    J Cancer Res Clin Oncol. 2019;145:737-746.
    PubMed     Text format     Abstract available
    
    
    February 2019
17. LIN XR, Zhou XL, Feng Q, Pan XY, et al
    CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
    J Cancer Res Clin Oncol. 2019 Feb 22. pii: 10.1007/s00432-019-02857.
    PubMed     Text format     Abstract available
    
    
    
18. PARK HL, Yoo IR, Boo SH, Park SY, et al
    Does FDG PET/CT have a role in determining adjuvant chemotherapy in surgical margin-negative stage IA non-small cell lung cancer patients?
    J Cancer Res Clin Oncol. 2019 Feb 13. pii: 10.1007/s00432-019-02858.
    PubMed     Text format     Abstract available
    
    
    
19. MENG D, Meng M, Luo A, Jing X, et al
    Effects of VEGFR1(+) hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells.
    J Cancer Res Clin Oncol. 2019;145:411-427.
    PubMed     Text format     Abstract available
    
    
    
20. MIYASHITA T, Omori T, Nakamura H, Sugano M, et al
    Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion.
    J Cancer Res Clin Oncol. 2019;145:373-381.
    PubMed     Text format     Abstract available
    
    
    January 2019
21. PENG F, Li Q, Niu SQ, Shen GP, et al
    ZWINT is the next potential target for lung cancer therapy.
    J Cancer Res Clin Oncol. 2019 Jan 14. pii: 10.1007/s00432-018-2823.
    PubMed     Text format     Abstract available
    
    
    
22. ZHANG J, Xiang C, Han Y, Teng H, et al
    Differential diagnosis of pulmonary enteric adenocarcinoma and metastatic colorectal carcinoma with the assistance of next-generation sequencing and immunohistochemistry.
    J Cancer Res Clin Oncol. 2019;145:269-279.
    PubMed     Text format     Abstract available
    
    
    
23. LIU C, Li Z, Wang S, Fan Y, et al
    FUT4 is involved in PD-1-related immunosuppression and leads to worse survival in patients with operable lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2019;145:65-76.
    PubMed     Text format     Abstract available
    
    
    December 2018
24. ZHUGE L, Huang Y, Wang S, Xie J, et al
    Preoperative brain MRI for clinical stage IA lung cancer: is routine scanning rational?
    J Cancer Res Clin Oncol. 2018 Dec 7. pii: 10.1007/s00432-018-2814.
    PubMed     Text format     Abstract available
    
    
    
25. RICCIUTI B, Genova C, De Giglio A, Bassanelli M, et al
    Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    J Cancer Res Clin Oncol. 2018 Dec 1. pii: 10.1007/s00432-018-2805.
    PubMed     Text format     Abstract available
    
    
    November 2018
26. WANG J, Wu N, Lv C, Yan S, et al
    Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy? A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stage IB patients.
    J Cancer Res Clin Oncol. 2018 Nov 24. pii: 10.1007/s00432-018-2801.
    PubMed     Text format     Abstract available
    
    
    
27. THORLACIUS-USSING J, Kehlet SN, Ronnow SR, Karsdal MA, et al
    Non-invasive profiling of protease-specific elastin turnover in lung cancer: biomarker potential.
    J Cancer Res Clin Oncol. 2018 Nov 22. pii: 10.1007/s00432-018-2799.
    PubMed     Text format     Abstract available
    
    
    
28. GUO T, Li J, Zhang L, Hou W, et al
    Multidimensional communication of microRNAs and long non-coding RNAs in lung cancer.
    J Cancer Res Clin Oncol. 2018 Nov 11. pii: 10.1007/s00432-018-2767.
    PubMed     Text format     Abstract available
    
    
    
29. ZOU SM, Li WH, Wang WM, Li WB, et al
    The gene mutational discrepancies between primary and paired metastatic colorectal carcinoma detected by next-generation sequencing.
    J Cancer Res Clin Oncol. 2018;144:2149-2159.
    PubMed     Text format     Abstract available
    
    
    October 2018
30. KORDIAK J, Szemraj J, Grabska-Kobylecka I, Bialasiewicz P, et al
    Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.
    J Cancer Res Clin Oncol. 2018 Oct 27. pii: 10.1007/s00432-018-2779.
    PubMed     Text format     Abstract available
    
    
    
31. YANG H, Xu J, Yao F, Liang S, et al
    Analysis of unexpected small cell lung cancer following surgery as the primary treatment.
    J Cancer Res Clin Oncol. 2018 Oct 20. pii: 10.1007/s00432-018-2766.
    PubMed     Text format     Abstract available
    
    
    
32. YAN X, Wang Q, Wang H, Li P, et al
    Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
    J Cancer Res Clin Oncol. 2018 Oct 6. pii: 10.1007/s00432-018-2764.
    PubMed     Text format     Abstract available
    
    
    September 2018
33. STRATMANN JA, Michels S, Hornetz S, Christoph DC, et al
    Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2018 Sep 22. pii: 10.1007/s00432-018-2754.
    PubMed     Text format     Abstract available
    
    
    
34. DE OLIVEIRA THA, do Amaral CM, de Franca Sao Marcos B, Nascimento KCG, et al
    Presence and activity of HPV in primary lung cancer.
    J Cancer Res Clin Oncol. 2018 Sep 17. pii: 10.1007/s00432-018-2748.
    PubMed     Text format     Abstract available
    
    
    August 2018
35. LENG Q, Tsou JH, Zhan M, Jiang F, et al
    Fucosylation genes as circulating biomarkers for lung cancer.
    J Cancer Res Clin Oncol. 2018 Aug 12. pii: 10.1007/s00432-018-2735.
    PubMed     Text format     Abstract available
    
    
    
36. STUMPF C, Kaemmerer D, Neubauer E, Sanger J, et al
    Somatostatin and CXCR4 expression patterns in adenocarcinoma and squamous cell carcinoma of the lung relative to small cell lung cancer.
    J Cancer Res Clin Oncol. 2018 Aug 3. pii: 10.1007/s00432-018-2722.
    PubMed     Text format     Abstract available
    
    
    
37. LIU XL, Zuo R, Ou WB
    The hippo pathway provides novel insights into lung cancer and mesothelioma treatment.
    J Cancer Res Clin Oncol. 2018 Aug 3. pii: 10.1007/s00432-018-2727.
    PubMed     Text format     Abstract available
    
    
    July 2018
38. FAEHLING M, Schwenk B, Kramberg S, Fallscheer S, et al
    Second malignancy in non-small cell lung cancer (NSCLC): prevalence and overall survival (OS) in routine clinical practice.
    J Cancer Res Clin Oncol. 2018 Jul 30. pii: 10.1007/s00432-018-2714.
    PubMed     Text format     Abstract available
    
    
    
39. ZHANG Y, Zhang M, Jiang Y, Li X, et al
    Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China.
    J Cancer Res Clin Oncol. 2018 Jul 24. pii: 10.1007/s00432-018-2718.
    PubMed     Text format     Abstract available
    
    
    
40. QIU J, Li X, He Y, Sun D, et al
    Distinct subgroup of the Ras family member 3 (DIRAS3) expression impairs metastasis and induces autophagy of gastric cancer cells in mice.
    J Cancer Res Clin Oncol. 2018 Jul 24. pii: 10.1007/s00432-018-2708.
    PubMed     Text format     Abstract available
    
    
    
41. LUO W, Wang Z, Tian P, Li W, et al
    Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials.
    J Cancer Res Clin Oncol. 2018 Jul 17. pii: 10.1007/s00432-018-2707.
    PubMed     Text format     Abstract available
    
    
    
42. YANG J, Zhang Y, Sun X, Gusdon AM, et al
    The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study.
    J Cancer Res Clin Oncol. 2018 Jul 12. pii: 10.1007/s00432-018-2702.
    PubMed     Text format     Abstract available
    
    
    
43. PENG Y, Chen Y, Zhang X, Yang Y, et al
    Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy.
    J Cancer Res Clin Oncol. 2018;144:1339-1346.
    PubMed     Text format     Abstract available
    
    
    June 2018
44. OKUMA Y, Kashima J, Watanabe K, Homma S, et al
    Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations.
    J Cancer Res Clin Oncol. 2018 Jun 1. pii: 10.1007/s00432-018-2681.
    PubMed     Text format     Abstract available
    
    
    
45. LI C, Liu H, Zhang B, Gong L, et al
    Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors.
    J Cancer Res Clin Oncol. 2018;144:1079-1086.
    PubMed     Text format     Abstract available
    
    
    
46. WANG Y, Zheng D, Zheng J, Huang Q, et al
    Predictors of recurrence and survival of pathological T1N0M0 invasive adenocarcinoma following lobectomy.
    J Cancer Res Clin Oncol. 2018;144:1015-1023.
    PubMed     Text format     Abstract available
    
    
    May 2018
47. ZHU Y, Tang K, Zhao F, Zang Y, et al
    End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer.
    J Cancer Res Clin Oncol. 2018 May 29. pii: 10.1007/s00432-018-2673.
    PubMed     Text format     Abstract available
    
    
    
48. XU J, Zhao X, He D, Wang J, et al
    Loss of EGFR confers acquired resistance to AZD9291 in an EGFR-mutant non-small cell lung cancer cell line with an epithelial-mesenchymal transition phenotype.
    J Cancer Res Clin Oncol. 2018 May 24. pii: 10.1007/s00432-018-2668.
    PubMed     Text format     Abstract available
    
    
    
49. HU C, Zhu P, Xia Y, Hui K, et al
    Role of the NRP-1-mediated VEGFR2-independent pathway on radiation sensitivity of non-small cell lung cancer cells.
    J Cancer Res Clin Oncol. 2018 May 17. pii: 10.1007/s00432-018-2667.
    PubMed     Text format     Abstract available
    
    
    
50. HANKE NT, Imler E, Marron MT, Seligmann BE, et al
    Characterization of carfilzomib-resistant non-small cell lung cancer cell lines.
    J Cancer Res Clin Oncol. 2018 May 15. pii: 10.1007/s00432-018-2662.
    PubMed     Text format     Abstract available
    
    
    
51. MEIER-SCHROERS M, Schild HH, Thomas D
    Response to "Commentary on: Lung cancer screening with MRI: results of the first screening round": Ngam Pei Ing et al.
    J Cancer Res Clin Oncol. 2018 May 14. pii: 10.1007/s00432-018-2660.
    PubMed     Text format    
    
    
    
52. NGAM PI, Ling JZJ
    "Commentary on: Lung cancer screening with MRI: results of the first screening round"-Michael Meier-Schroers et al.
    J Cancer Res Clin Oncol. 2018 May 10. pii: 10.1007/s00432-018-2655.
    PubMed     Text format    
    
    
    
53. BOYARSKIKH UA, Shadrina AS, Smetanina MA, Tsepilov YA, et al
    Mycoplasma hyorhinis reduces sensitivity of human lung carcinoma cells to Nutlin-3 and promotes their malignant phenotype.
    J Cancer Res Clin Oncol. 2018 May 8. pii: 10.1007/s00432-018-2658.
    PubMed     Text format     Abstract available
    
    
    
54. WANG K, Qu X, Liu S, Yang X, et al
    Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
    J Cancer Res Clin Oncol. 2018 May 4. pii: 10.1007/s00432-018-2653.
    PubMed     Text format     Abstract available
    
    
    
55. NAKASONE S, Mimaki S, Ichikawa T, Aokage K, et al
    Podoplanin-positive cancer-associated fibroblast recruitment within cancer stroma is associated with a higher number of single nucleotide variants in cancer cells in lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2018;144:893-900.
    PubMed     Text format     Abstract available
    
    
    
56. ZHANG L, Li J, Lv X, Guo T, et al
    MID1-PP2A complex functions as new insights in human lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2018;144:855-864.
    PubMed     Text format     Abstract available
    
    
    
57. UEDA T, Aokage K, Nishikawa H, Neri S, et al
    Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung.
    J Cancer Res Clin Oncol. 2018;144:835-844.
    PubMed     Text format     Abstract available
    
    
    April 2018
58. FAEHLING M, Achenbach J, Staib P, Steffen U, et al
    Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
    J Cancer Res Clin Oncol. 2018 Apr 23. pii: 10.1007/s00432-018-2649.
    PubMed     Text format     Abstract available
    
    
    
59. ROJKO L, Reiniger L, Teglasi V, Fabian K, et al
    Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients.
    J Cancer Res Clin Oncol. 2018 Apr 19. pii: 10.1007/s00432-018-2642.
    PubMed     Text format     Abstract available
    
    
    
60. ELSAYAD K, Samhouri L, Scobioala S, Haverkamp U, et al
    Is tumor volume reduction during radiotherapy prognostic relevant in patients with stage III non-small cell lung cancer?
    J Cancer Res Clin Oncol. 2018 Apr 5. pii: 10.1007/s00432-018-2640.
    PubMed     Text format     Abstract available
    
    
    
61. AKTAS ON, Ozturk AB, Erman B, Erus S, et al
    Role of natural killer cells in lung cancer.
    J Cancer Res Clin Oncol. 2018 Apr 3. pii: 10.1007/s00432-018-2635.
    PubMed     Text format     Abstract available
    
    
    
62. YUAN Y, Ma G, Zhang Y, Chen H, et al
    Presence of micropapillary and solid patterns are associated with nodal upstaging and unfavorable prognosis among patient with cT1N0M0 lung adenocarcinoma: a large-scale analysis.
    J Cancer Res Clin Oncol. 2018;144:743-749.
    PubMed     Text format     Abstract available
    
    
    
63. LI J, You W, Zheng D, Yan B, et al
    A comprehensive evaluation of clinicopathologic characteristics, molecular features and prognosis in lung adenocarcinoma with solid component.
    J Cancer Res Clin Oncol. 2018;144:725-734.
    PubMed     Text format     Abstract available
    
    
    March 2018
64. SIKARIA D, Tu YN, Fisler DA, Mauro JA, et al
    Identification of specific feed-forward apoptosis mechanisms and associated higher survival rates for low grade glioma and lung squamous cell carcinoma.
    J Cancer Res Clin Oncol. 2018;144:459-468.
    PubMed     Text format     Abstract available
    
    
    
65. XU X, Yu S, Sun W, Qin X, et al
    MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.
    J Cancer Res Clin Oncol. 2018;144:431-438.
    PubMed     Text format     Abstract available
    
    
    January 2018
66. JIANG MM, Mai ZT, Wan SZ, Chi YM, et al
    Microarray profiles reveal that circular RNA hsa_circ_0007385 functions as an oncogene in non-small cell lung cancer tumorigenesis.
    J Cancer Res Clin Oncol. 2018 Jan 25. pii: 10.1007/s00432-017-2576.
    PubMed     Text format     Abstract available
    
    
    
67. MATSUO Y, Shiomi K, Sonoda D, Mikubo M, et al
    Molecular alterations in a new cell line (KU-Lu-MPPt3) established from a human lung adenocarcinoma with a micropapillary pattern.
    J Cancer Res Clin Oncol. 2018;144:75-87.
    PubMed     Text format     Abstract available
    
    
    
68. ZHANG Y, Ma Y, Li Y, Shen X, et al
    Are exon 19 deletions and L858R different in early stage lung adenocarcinoma?
    J Cancer Res Clin Oncol. 2018;144:165-171.
    PubMed     Text format     Abstract available
    
    
    
69. KIRCHBERGER MC, Schilling B, Haferkamp S, Bosserhoff A, et al
    Can checkpoint inhibitor therapy improve response to chemotherapy?
    J Cancer Res Clin Oncol. 2018;144:183-185.
    PubMed     Text format    
    
    
    December 2017
70. XU X, Li N, Zhao R, Zhu L, et al
    Targeted next-generation sequencing for analyzing the genetic alterations in atypical adenomatous hyperplasia and adenocarcinoma in situ.
    J Cancer Res Clin Oncol. 2017;143:2447-2453.
    PubMed     Text format     Abstract available
    
    
    November 2017
71. JIA PL, Zhang C, Yu JJ, Xu C, et al
    The risk of lung cancer among cooking adults: a meta-analysis of 23 observational studies.
    J Cancer Res Clin Oncol. 2017 Nov 21. doi: 10.1007/s00432-017-2547.
    PubMed     Text format     Abstract available
    
    
    
72. XIONG Y, Wang L, Wang S, Wang M, et al
    SIRT3 deacetylates and promotes degradation of P53 in PTEN-defective non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2017 Nov 4. doi: 10.1007/s00432-017-2537.
    PubMed     Text format     Abstract available
    
    
    
73. KIM HR, Kim SY, Kim CH, Yang SH, et al
    Sex-specific incidence of EGFR mutation and its association with age and obesity in lung adenocarcinomas: a retrospective analysis.
    J Cancer Res Clin Oncol. 2017;143:2283-2290.
    PubMed     Text format     Abstract available
    
    
    October 2017
74. WEI S, Tian J, Song X, Wu B, et al
    Causes of death and competing risk analysis of the associated factors for non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.
    J Cancer Res Clin Oncol. 2017 Oct 4. doi: 10.1007/s00432-017-2522.
    PubMed     Text format     Abstract available
    
    
    
75. WANG Y, Wang R, Zheng D, Han B, et al
    The indication of completion lobectomy for lung adenocarcinoma </=3 cm after wedge resection during surgical operation.
    J Cancer Res Clin Oncol. 2017;143:2095-2104.
    PubMed     Text format     Abstract available
    
    
    
76. POWROZEK T, Mlak R, Dziedzic M, Malecka-Massalska T, et al
    Analysis of primary-miRNA-3662 and its mature form may improve detection of the lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2017;143:1941-1946.
    PubMed     Text format     Abstract available
    
    
    September 2017
77. MEIER-SCHROERS M, Homsi R, Skowasch D, Buermann J, et al
    Lung cancer screening with MRI: results of the first screening round.
    J Cancer Res Clin Oncol. 2017 Sep 20. doi: 10.1007/s00432-017-2521.
    PubMed     Text format     Abstract available
    
    
    
78. THULER LCS, Costa GJ, de Mello MJG, Ferreira CG, et al
    Response to "Commentary on: Undertreatment trend in elderly lung cancer patients in Brazil"-Jing-lan Tang, Chun-jie Hou.
    J Cancer Res Clin Oncol. 2017 Sep 5. doi: 10.1007/s00432-017-2511.
    PubMed     Text format    
    
    
    
79. TAO H, Zhang Y, Li Q, Chen J, et al
    Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review.
    J Cancer Res Clin Oncol. 2017 Sep 5. doi: 10.1007/s00432-017-2516.
    PubMed     Text format     Abstract available
    
    
    August 2017
80. TANG JL, Hou CJ
    Commentary on: undertreatment trend in elderly lung cancer patients in Brazil.
    J Cancer Res Clin Oncol. 2017 Aug 29. doi: 10.1007/s00432-017-2498.
    PubMed     Text format    
    
    
    
81. GU C, Wang R, Pan X, Huang Q, et al
    Sublobar resection versus lobectomy in patients aged </=35 years with stage IA non-small cell lung cancer: a SEER database analysis.
    J Cancer Res Clin Oncol. 2017 Aug 17. doi: 10.1007/s00432-017-2499.
    PubMed     Text format     Abstract available
    
    
    
82. LIAO YH, Li CI, Lin CC, Lin JG, et al
    Traditional Chinese medicine as adjunctive therapy improves the long-term survival of lung cancer patients.
    J Cancer Res Clin Oncol. 2017 Aug 12. doi: 10.1007/s00432-017-2491.
    PubMed     Text format     Abstract available
    
    
    
83. MININA VI, Soboleva OA, Glushkov AN, Voronina EN, et al
    Polymorphisms of GSTM1, GSTT1, GSTP1 genes and chromosomal aberrations in lung cancer patients.
    J Cancer Res Clin Oncol. 2017 Aug 2. doi: 10.1007/s00432-017-2486.
    PubMed     Text format     Abstract available
    
    
    
84. HASHIMOTO H, Suda Y, Miyashita T, Ochiai A, et al
    A novel method to generate single-cell-derived cancer-associated fibroblast clones.
    J Cancer Res Clin Oncol. 2017;143:1409-1419.
    PubMed     Text format     Abstract available
    
    
    May 2017
85. WU X, Ma W, Zhou Q, Yan H, et al
    AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.
    J Cancer Res Clin Oncol. 2017 May 27. doi: 10.1007/s00432-017-2408.
    PubMed     Text format     Abstract available
    
    
    April 2017
86. WIECZOREK SA, Breitenbuecher F, Soni A, Paul-Konietzko K, et al
    Deregulated BCL-2 family proteins impact on repair of DNA double-strand breaks and are targets to overcome radioresistance in lung cancer.
    J Cancer Res Clin Oncol. 2017 Apr 21. doi: 10.1007/s00432-017-2427.
    PubMed     Text format     Abstract available
    
    
    
87. COSTA GJ, de Mello MJ, Ferreira CG, Thuler LC, et al
    Undertreatment trend in elderly lung cancer patients in Brazil.
    J Cancer Res Clin Oncol. 2017 Apr 7. doi: 10.1007/s00432-017-2412.
    PubMed     Text format     Abstract available
    
    
    
88. TAO H, Tanaka T, Okabe K
    Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2017 Apr 5. doi: 10.1007/s00432-017-2405.
    PubMed     Text format     Abstract available
    
    
    March 2017
89. HASTINGS RH, Montgrain PR, Quintana RA, Chobrutskiy B, et al
    Lung carcinoma progression and survival versus amino- and carboxyl-parathyroid hormone-related protein expression.
    J Cancer Res Clin Oncol. 2017 Mar 25. doi: 10.1007/s00432-017-2396.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: